Israeli pill shows promise for diabetes

TEL AVIV, Israel — Oramed Pharmaceuticals, the Israeli drugmaker seeking to develop the first oral pill for diabetes, said a trial on type 2 diabetes patients showed that the medicine has promising therapeutic potential.

The one-week study of 30 patients also met safety goals, the Jerusalem-based company said Thursday. Oramed plans to follow the mid-stage trial with another study later this year.

“The results we announced today give us confidence about the chances of success in a bigger trial going forward,” Chief Executive Officer Nadav Kidron said at a press conference Thursday at the Tel Aviv Stock Exchange. “We are also excited about the potential of this drug for type 1 diabetes.”

The results bring Oramed, whose stock has more than tripled in the past year, a step closer to doing something no company has ever done: develop oral insulin. The technology has eluded scientists for decades and Novo Nordisk, a Danish developer of diabetes products valued at about $104 billion, has yet to develop a pill to replace daily shots.

While Oramed is years away from a potential approval, it’s taking advantage of the growing attention to raise money. The company raised $16 million on Dec. 25, five days after it said it had successful results in an early-stage type 1 diabetes study. On Jan. 24, the company filed to raise as much as $100 million.

The market for drugs to treat diabetes is likely to grow to more than $58 billion in 2018 from $35 billion in 2012, Standard &Poor’s wrote in an October report.

Diabetes afflicted 371 million people and killed 4.8 million worldwide in 2012, according to the International Diabetes Federation. People with type 2 diabetes don’t produce enough insulin, a hormone that helps the body use or store blood sugar, or can’t use the insulin properly. The illness, the most common form of diabetes, often strikes people over the age of 40, and is tied to obesity and sedentary lifestyles.

The drugmaker’s Protein Oral Delivery, or POD, technology, is based on research by scientists at Jerusalem’s Hadassah Medical Center.

The Phase IIa trial detailed Thursday will be followed by a Phase IIb study.

More in Local News

At long last, a church of his own

After years of filling in elsewhere, Hallack Greider is the new pastor at Maplewood Presbyterian.

Judge: Lawmakers’ emails, texts subject to public disclosure

News organizations had sued to challenge the Legislature’s claim that members were exempt.

Herald photos of the week

A weekly collection of The Herald’s top images by staff photographers and… Continue reading

Outgoing councilwoman honored by Marysville Fire District

The Marysville Fire District in December honored outgoing City Councilwoman Donna Wright… Continue reading

Everett district relents on eminent domain moving expenses

Homeowners near Bothell still must be out by April to make way for a planned new high school.

Their grown children died, but state law won’t let them sue

Families are seeking a change in the state’s limiting wrongful-death law.

Officials rule train-pedestrian death an accident

The 37-year-old man was trying to move off the tracks when the train hit him, police say.

Number of flu-related deaths in county continues to grow

Statewide, 86 people have died from the flu, most of whom were 65 or older.

Ex-Monroe cop re-arrested after losing sex crime case appeal

He was sentenced to 14 months in prison but was free while trying to get his conviction overturned.

Most Read